Shots: The global companies modernize their alliance as of Jan 01, 2020 to completely focus their expertise and investment on the development and commercialization of Jardiance (empagliflozin) for T2D, HF […]readmore
Tags : Lilly
Shots: The US FDA approval is based on P-III SAMURAI and SPARTAN, evaluated the safety and efficacy of Reyvow vs PBO for the acute treatment of migraine in adults, resulted […]readmore
Shots: The P-III AWARD-11 study results involve assessing of Trulicity (3.0mg/4.5mg, qw) vs Trulicity (1.5mg, qw) in 1842 patients with type 2 diabetes for 52wks. The P-III AWARD study resulted […]readmore
Shots: Centrexion to receive $47.5M upfront, up to $950M as development, regulatory & commercial milestones and royalties on sales of product. Lilly to get exclusive WW rights for CNTX-0290 & […]readmore
Shots: The P-III COAST-X study involves assessing of Taltz (ixekizumab) vs PBO in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who are biologic disease-modifying anti-rheumatic drug (bDMARD) naive for 52wks. The […]readmore
Shots: Avidity to receive $20M upfront, $15M equity investment, $405M as development, regulatory & commercial milestones for each target and royalties on sales. Lilly to get WW rights to develop […]readmore
Shots: ImmuNext to receive $40M upfront, $565M as development & commercialization milestones and royalties on sales of products. Lilly to get an exclusive WW licence to develop & commercialize novel […]readmore
Shots: The P-III A4091059 study involves assessing of tanezumab (5mg,10mg) vs PBO vs tramadol (prolonged release) in 1,832 in the ratio 2:2:2:3 with moderate-to-severe chronic low back pain (CLBP) in […]readmore
Shots: Lilly to acquire Hydra, in all stock transaction with its all pre-clinical pain program of TRPA1 antagonists The focus of the acquisition is to develop treatments for chronic pain and understand TRP […]readmore
Shots: AC Immune to receive $80M upfront, $1760M milestones and royalties on sales and Lilly to get WW commercialization rights for AC Immune’s tau aggregation inhibitors and will invest $50M as convertible notes […]readmore